Renin–angiotensin system (RAS) blockade is the mainstay of CKD therapy especially for diabetic kidney disease and hypertensive kidney disease, including angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) [4,5]. This evidence concerns the gene REN and chronic kidney disease.